Faeth Therapeutics, Inc. (FTH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | -5 | - |
| Operating profit | $m | -22 | - | ||||||
| Net profit | $m | -20 | -37 | -49 | -34 | -30 | -21 | - | - |
| EPS reported | $ | -16.72 | -34.65 | ||||||
| Operating cashflow per share | $ | -16.22 | -6.00 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -16.24 | -6.00 | ||||||
| Free cash flow | $m | -20 | -34 | ||||||
| Net debt | $m | -21 | -186 | ||||||
| Book value equity | $m | 19 | - | ||||||
| Book value per share | $ | 14.75 | 30.65 | ||||||
| Number of shares | m | 1.26 | 5.64 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.72 | 1.06 | ||||||
| P/S LTM | x | 0.00 | -2.77 | ||||||
| P/FCF LTM | x | -0.66 | -0.40 | ||||||
| EV/EBITDA LTM | x | -0.30 | -0.03 | ||||||
| EV/Sales LTM | x | 0.00 | -166.43 | ||||||
| Earnings Yield LTM | % | -1.57% | -1.07% | ||||||
| FCF Yield | % | -152.16% | -251.72% | ||||||
| Quality | |||||||||
| ROE | % | -113.41% | -192.76% | ||||||
| ROIC | % | -1.11% | -1.10% | ||||||
| Operating margin | % | 0.00% | +40.99% | ||||||
| Gross margin | % | 0.00% | +27.41% | ||||||
| FCF/Sales | % | - | +698.04% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -13.56 | -57.20 | ||||||
| Net Debt/EBITDA | x | 0.34 | 0.13 | ||||||
| EBIT/Net interest | x | -696.50 | -22,091.11 | ||||||
| Net debt/market cap | % | +0.44% | 0.00% | ||||||
| Net debt/Equity | x | -1.14 | - | ||||||
| Gross debt/equity | x | 0.08 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free